Drugs / Epimedium Prenylflavonoids Extract
Epimedium Prenylflavonoids Extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02931305 | Oct 2016 → Jan 2017 | cardiovascular disorder, osteoporosis | National University Hospital, Singapore | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epimedium Prenylflavonoids Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02931305 ↗ |
| Action | Inhibit | “inhibits bone resorption” NCT02931305 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Traditional Chinese Medicine (TCM), Epimedium” NCT02931305 ↗ |
| Route | Oral | “Single oral doses of EP (370 mg, 740 mg and 1110 mg) capsules would be orally administered.” NCT02931305 ↗ |